Access to Treatment

The Epilepsy Foundation actively advocates at the state and federal level for public policies that improve access to quality care for people living with epilepsy. 

For people living with epilepsy, timely access to appropriate care and effective coverage for epilepsy medications is a critical concern. Anti-epilepsy drugs (AEDs) are the most common and most cost effective treatment for controlling and/or reducing seizures. To delay, change, limit, or deny access to medications could be extremely dangerous. 

We raise awareness with policy makers about the critical need for people living with epilepsy to have timely access to the right medications. Patients with epilepsy who experience a delay in accessing their medication due to prior authorization and step therapy requirements, high cost-sharing, medication substitutions without physician and patient consent, and onerous drug monitoring requirements, are at a high risk for developing breakthrough seizures and related complications, including Sudden Unexpected Death in Epilepsy (SUDEP). 

We are leading advocacy activities at the state and federal level to improve access to care by urging policy makers to address limited benefits, high cost-sharing, and lack of transparency and uniformity in Marketplace plans, which make it hard to individuals, especially those living with chronic health conditions like epilepsy, to access the care they need. Learn more at (link to ACA Implementation page). 

Learn more about legislation to address prior authorization and step therapy requirements, high cost-sharing, medication substitutions, and onerous drug monitoring requirements.

Access to Care Advocacy CHIP letter